Top Back to top

Publications

by

The five latest EBMT papers published in peer-reviewed journals

Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT
Ruutu T    et al.
Bone Marrow Transplant.    

Outcome of allogeneic hematopoietic stem cell transplantation in patients over 69 years of age with acute myeloid leukemia: on behalf of the acute leukemia working party of the EBMT.
Ringdén O et al.
Biol Blood Marrow Transplant.

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.
Piemontese S et al.
J Hematol Oncol.

Comparable Long-Term Outcome after Allogeneic StemShimoni A-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT.
Shimoni A et al.
Biol Blood Marrow Transplant.

Current practice in vitamin D management in Allogeneic Haematopoietic Stem Cell Transplantation: a survey by the Transplant Complications Working Party of the EBMT.
Ros-Soto J et al.
Biol Blood Marrow Transplant.
 

Top cited papers published so far this year in Bone Marrow Transplantation

Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia

High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study 

Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation 

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract 

Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis

Source: Clarivate Analytics

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org